Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



MS Patients Weigh In on Physician Conflicts of Interest in New Study

Multiple sclerosis (MS) is difficult enough for those who have it, causing damage to the nervous system, difficulty with movement, sensation, numbness, loss of vision and pain. People with MS rely on medications and the care of physicians to manage their symptoms and the progressions of the disease. But what happens when physicians entrusted to care for MS patients have conflicts of interest, due to connections with the pharmaceutical industry, such as possible perks provided by specific drug manufacturers? A new study focuses on how MS patients feel about physician conflicts of interest — and indicates that these types of relationships are in fact of concern to people with MS.

Researchers at University of Vermont, led by neurologist and MS specialist Andrew Solomon, M.D., conducted an anonymous survey to measure patient attitudes about this topic. Their interest was based on the fact that industry relationships often go undisclosed.  The findings appear in an OnlineFirst article in the Multiple Sclerosis Journal.

Solomon stated “…direct industry financial support of physicians, physician practices, and academic departments involved in MS therapy-related multicenter ISCTs are an infrequently acknowledged source of potential physician conflict of interest, so we wanted to gauge patients’ perspective on the issue.”

The survey participants included 597 MS patients from the United States. A total of 552 completed the entire survey. Responses from people with MS who had participated and those who had not participated in medication clinical trials in the past were captured in the study.

Most of the respondents felt that disclosure of physician-pharmaceutical company relationships was important. “Compensation toward principal investigator salary” was considered to be the most important relationship among the types of physician-industry financial relationships available for selection in the survey.

“While our study demonstrates the importance of disclosure of information concerning physician conflicts of interest in MS [medication clinical trials] to potential participants, our findings — drawn from a single survey — are limited,” remarked Solomon. “More research on patient perspectives on this important issue, as well as how to most effectively incorporate this information into the consent process for research studies, is needed.”

Solomon noted that “avoidance or minimization of potential conflicts of interest is the goal.”

The study authors noted that despite possible conflicts of interest, “Physician-industry collaborations have advanced important scientific knowledge and helped develop new therapies that have significantly improved the lives of patients with MS.”

Important advances in the treatment of MS, which is currently inadequately treated and managed, need to move forward. Hopefully this can occur without excessive bias affecting the opinions of physicians conducting clinical trials. According to the results of this study, a majority of people with MS would prefer knowing when their attending physician has a working relationship with the pharmaceutical industry so that they can make the most informed decisions about their own health.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News